Closing the data loop in AI-driven drug discovery
Eroom's Law just met its match. Here's how AI is closing the loop on drug discovery economics.
Why it matters
AI is reshaping pharmaceutical R&D economics by accelerating drug discovery timelines and reducing development costs—a critical shift for biotech investors and pharma leaders rethinking capital allocation in an AI-first world.
The key facts
8 to knowDrug development cost has doubled every 9 years since 1950s (Eroom's Law)
Current timeline: 10-15 years average to market
Article focuses on 'closing the data loop' — feedback mechanisms in AI-driven discovery
Published in MIT Technology Review (credible academic/industry source)
Eroom's Law: pharmaceutical development costs double every 9 years since the 1950s
Current drug development timeline: 10-15 years average
AI application focus: closing data loops in discovery pipeline
Industry context: market defined by first-mover advantage pressure
Go to the source
MIT Technology Reviewtechnologyreview.com
Publisher excerpt: Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new…